Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
by on Monday, April 16th, 2012 | No Comments
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EC145; Drug: EC145 + Docetaxel; Drug: Docetaxel; Drug: EC20
Sponsor: Endocyte
Recruiting – verified April 2012
Go here to see the original: Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer